The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in
patients with sickle cell disease and thalassemia. The purpose of the study is to assess the
safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell
transplantation.
Phase:
Phase 1
Details
Lead Sponsor:
Catherine Bollard
Collaborators:
Children's National Research Institute Children's Research Institute